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ABSTRACT Calponin is an actin filament-associated protein significantly involved in the 
regulation of the cellular motility. Some data have indicated that overproduction of cal-
ponin in basal cell carcinoma (BCC) of the skin may be responsible for local tumor inva-
siveness and more aggressive biological behavior. We studied the immunohistochemical 
expression of calponin in a set of cutaneous BCCs, in order to clarify whether the presence 
of calponin in cancer cells may be a predictor of invasive tumor growth. The study group 
consisted of 37 primary BCCs categorized into a non-infiltrative subgroup (5 superficial, 
16 nodular subtypes) and infiltrative subgroup (9 nodular-infiltrative, 7 infiltrative sub-
types). A specific monoclonal antibody against calponin was used for staining. Expres-
sion of calponin in tumor tissue was found in 72.9% (27/37) of the cases, though staining 
intensity was relatively weak. In superficial, nodular, nodular-infiltrative, and infiltrative 
BCC subtypes, calponin positivity was found in 80% (4/5), 75% (12/16), 66.7% (6/9), and 
71.5% (5/7), respectively. We did not confirm a significant correlation between expres-
sion of calponin and given, non-infiltrative, and infiltrative BCC subgroups. Furthermore, 
we found seven BCCs (18.9%) with striking immunoreactivity for calponin in adjacent 
peritumorous stroma. There was a significant association between stromal immunoreac-
tivity for calponin and tumor growth histomorphology being positive only in BCCs with 
infiltrative growth features. Our study has shown that neoplastic cells in cutaneous BCC 
commonly produce calponin regardless of histological subtype. Expression of calponin 
in tumor tissue was not associated with the aggressive tumor phenotype. However, since 
some BCCs with infiltrative growth patterns strongly expressed calponin in peritumor-
ous stroma, this finding could more reliably reflect the biological behavior of cancer and 
should be better explained in the future. 
KEY WORDS: basal cell carcinoma, calponin, immunohistochemistry
INTRODUCTION
Basal cell carcinoma (BCC) of the skin is currently 
the most common malignancy in humans (1-3). In 
contrast to most other cancers, it generally has a fa-
vourable clinical course, growing slowly and expand-
ing only locally (1-3). However, some cases show ag-
gressive behavior, rapidly infiltrating deeper tissue 
structure, and sometimes (although very rarely) giv-
ing rise to metastatic spread (1,2). Although many 
various molecular markers have been studied in cuta-
neous BCC (4), it is still not clearly understood which 
of them are directly responsible for aggressive tumor 
behavior, and, conversely, which potentially prevent 
cancer cells to metastasize. Because BCC has a purely 
epithelial origin, it naturally expresses a broad spec-
trum of epithelial biomarkers, such as cytokeratins 
or E-cadherin. Interestingly, this neoplasia may also 
exhibit some mesenchymal/myoepithelial markers, 
e.g. alpha-smooth muscle actin (5-9) and calponin 
(5,10), which are unusual for “ordinary” carcinomas. 
Both these cytoplasmic proteins possess contractile 
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properties and are thus significantly involved in the 
regulation of cell kinetics and are largely responsi-
ble for cellular motility. Since normal epithelial cells 
have not a marked tendency to move, alpha-smooth 
muscle actin (α–SMA) and calponin are only sparsely 
found in their cytoplasm. On the other hand, their in-
tracytoplasmic overproduction generally suggests an 
increased cellular mobility and hence a higher inva-
sive potential of malignant tumor cells. Cytoskeletal 
reorganizations, especially alterations of contractile 
tension generated by the actin-myosin complex, are 
of central importance in the development of the phe-
notype of morphologically transformed neoplastic 
cells with invasive behavior. Of the proteins described 
above, α–SMA has been more intensively studied in 
cutaneous BCC (5,6,7,9), including our recent study 
(8). However, to the best of our knowledge, there are 
only two studies (5,10) dealing with the expression of 
calponin in BCC of the skin. Since these papers gave 
contradictory results, this topic is still far from clear. 
Therefore, we focused on immunohistochemical 
analysis of calponin expression in a set of cutaneous 
BCCs in order to clarify whether the presence of cal-
ponin in cancer cells may be a predictor of invasive 
tumor growth. 
PATIENTS AND METHODS
Patients and tumor specimens 
Biopsy samples from 37 chosen cases of primary 
cutaneous BCCs from various topographic locations 
were included in this study. They were obtained from 
23 subjects (17 men, 6 women) aged 35-91 years 
(mean 73.5 years). All patients were treated at the 
clinical departments of the Faculty Hospital in Zilina 
(Slovakia) and all biopsy samples were histopatho-
logically investigated at the Department of Pathol-
ogy in the Faculty Hospital in Zilina during the year 
2014. For the purpose of this study, we selected a set 
of representative samples of cutaneous BCCs includ-
ing four histomorphological subtypes: superficial (5 
cases), nodular (16 cases), mixed nodular-infiltrative 
(9 cases), and pure infiltrative (7 cases). They were 
divided into two separate subgroups for statistical 
analysis. The first subgroup was comprised of 21 in-
dolent (non-infiltrative) BCC subtypes (superficial 
and nodular). The second subgroup was comprised 
of 16 BCCs with an (at least focal) infiltrative growth 
pattern (mixed nodular-infiltrative and infiltrative 
subtypes). Only samples with enough tumor tissue in 
the paraffin-embedded blocks to harvest appropriate 
slides for immunohistochemistry were chosen. 
Immunohistochemistry 
Biopsy samples were routinely processed and im-
munohistochemically stained for calponin according 
to the manufacturer’s instructions. Representative 
4 μm tissue sections on silanized slides were baked 
for 2 hours in an oven at 56 °C. The sections were 
then deparaffinized in xylene, rehydrated in a series 
of descending ethanol concentrations, and treated 
with microwaves in a Dako Target Retrieval Solution 
(0.01 M citrate buffer, pH 6.0; Glostrup, Denmark) 
for 20 minutes. Endogenous peroxidase activity was 
blocked with 3% hydrogen peroxide for 5 minutes. 
Subsequently, specific monoclonal mouse anti-hu-
man antibodies against calponin (clone CALP, code 
M3556, DAKO, dilution 1:50) was used for staining. 
After incubation at ambient temperature for 20 min-
utes, post primary antibodies were applied and an 
immunoreaction was visualized by means of the DAB 
(3,3’-diaminobenzidine) detection chromogen solu-
tion (Dako REALTM EnVisionTM Detection System, code 
K5007). Slides were counterstained with Mayer’s he-
matoxylin, dehydrated, mounted, and finally evalu-
ated using a light microscope. Positive reactions on 
the myoepithelial layer of eccrine glands served as 
internal control.
 Data interpretation and statistical analysis
After including a total percentage of immunola-
belled tumor cells, according to Lee et al. (10), we ad-
opted the following four-titre semiquatitative scoring 
system: negative score 0 (<5% positive cells), score 
1+ (5-24% positive cells), score 2+ (25-49% positive 
cells), and score 3+ (≥50% positive cells). We consid-
ered a tumor to be calponin-positive if it had a score 
Figure 1. Diffuse expression of calponin (score 3+) 
within tumor tissue in superficial basal cell carcinoma 
(BCC) (clone calponin, DAKO, original magnification 
×120). 
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of 1+, 2+, or 3+. If the proportion of stained cells did 
not reach at least 5% (score 0), the result was classi-
fied as negative. In addition, we also evaluated adja-
cent peritumorous stroma for calponin expression, 
simply categorized as positive or negative. Data were 
collected in a databank, using a SPSS Statistics soft-
ware. For the statistical analysis, the chi-square test 
was employed and a P value of <0.05 was considered 
statistically significant.
RESULTS
In our series, calponin was expressed in 27 BCCs 
(72.9%) showing cytoplasmic staining within cancer 
cells. No nuclear or membranous immunoreactivity 
was detected. In superficial, nodular, nodular-infiltra-
tive, and infiltrative BCC subtypes, calponin positiv-
ity (defined as present in ≥5 % of immunolabelled 
tumor cells) was found in 80% (4/5), 75% (12/16), 
66.7% (6/9), and 71.5% (5/7), respectively (Figure 1, 
Figure 2, Figure 3). Within the positive group, a wide 
quantitative range of calponin expression was found. 
Overall, there were sixteen cases (59.3%) with a score 
of 1+, four cases (14.8%) with a score of 2+, and seven 
(25.9 %) cases with a score of 3+. We did not find a 
statistically significant correlation between immuno-
histochemical expression of calponin (present ver-
sus absent) and given, non-infiltrative, and (at least 
focally) infiltrative BCC subgroups (P=0.6). In mixed 
nodular-infiltrative BCC cases, the percentage of cal-
ponin-positive tumor tissue in both structural com-
ponents seemed to be about the same. As for stain-
ing intensity, the vast majority of BCCs showed weak 
cytoplasmic immunoreactivity and, although some 
cases contained areas with a more pronounced stain-
ing, it virtually never reached the degree observed in 
normal myoepithelial cells of the eccrine glands. 
In addition to calponin expression in tumor tissue, 
we registered seven BCCs (18.9%) with strong immu-
noreactivity for calponin in adjacent peritumorous 
stroma. All these cases manifested histomorphologi-
cally (at least focal) infiltrative growth features (three 
nodular-infiltrative subtypes and four infiltrative sub-
types). Among them, five (71.4%) were calponin-posi-
tive in tumor tissue and the remaining two (28.6%) 
were composed of only calponin-negative tumor cell 
populations (Figure 4). In contrast to epithelial can-
cer cells, however, stromal cells positive for calponin 
showed much stronger staining identical to that of 
Figure 2. Diffuse expression of calponin (score 3+) 
within tumor tissue in nodular basal cell carcinoma 
(BCC) (clone calponin, DAKO, original magnification 
×120). 
Figure 3. Diffuse expression of calponin (score 3+) 
within tumor tissue in infiltrative basal cell carcinoma 
(BCC) (clone calponin, DAKO, original magnification 
×120). 
Figure 4. Strong expression of calponin in the peri-
tumorous stroma in infiltrative basal cell carcinoma 
(BCC). Tumor nests are virtually negative (score 0) 
(clone calponin, DAKO, original magnification ×120). 
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the myoepithelial layer of the eccrine glands. More-
over, we observed a significant association between 
stromal immunoreactivity for calponin and tumor 
growth histomorphology being positive only in BCCs 
with infiltrative growth features (P<0.001). There was 
no correlation between calponin expression (present 
versus absent) in tumor tissue and peritumorous stro-
ma (P=0.3). A summary of the immunohistochemical 
findings in our set of BCCs investigated is presented 
in Table 1.
DISCUSSION
Calponin was first isolated from chicken gizzard 
smooth muscle cells as a 34 kDa actin- and calmodu-
lin-binding protein with a proposed function in the 
regulation of smooth muscle contraction (11). At 
present, it is defined as a family of actin filament-asso-
ciated proteins expressed in both smooth muscle and 
non-smooth muscle cells (12). Three isoforms have 
been identified in the vertebrates: a basic calponin 
(h1-calponin), a neutral calponin (h2-calponin), and 
an acidic calponin (h3-calponin) (12). These isoforms 
have distinct patterns of cell type-specific expression, 
indicating their functional diversities corresponding 
to the specific cellular microenvironment and/or the 
activity of different cell types (12). In routine biopsy 
practice, immunohistochemical detection of calponin 
principally serves to confirm smooth muscle and 
myoepithelial cell differentiation. Monoclonal anti-
human calponin antibodies (clone CALP), which are 
most commonly used in standard histopathological 
examination, stain positively with differentiated vis-
ceral and vascular smooth muscle cells, myoepithelial 
cells in the lobules, ducts, and galactophorous tissue 
of normal human breasts, as well as periacinar and 
periductal myoepithelial cells of the salivary glands. 
Thus, in addition to some mesenchymal neoplasms, 
calponin is expressed in benign or malignant hu-
man tumors of myoepithelial origin, for example in 
the salivary glands (13,14), in the breast (15), or in the 
skin (16).  
The results of our present study showed that im-
munohistochemical expression of calponin in tumor 
tissue occurred in 72.9% of all BCC cases. Therefore 
we may conclude this is a common feature, although 
staining intensity as such is relatively weak. This find-
ing is remarkable, because BCC of the skin does not 
exhibit smooth muscle or myoepithelial differen-
tiation. Lee et al. (10), who first described this phe-
nomenon, presumed that BCC cells which produce 
calponin might acquire the myoepithelium-like con-
tractile feature and hence enhance their invasiveness. 
They studied 32 cutaneous BCCs consisting of 18 
cases of nodular and 14 cases of infiltrative or mixed 
nodular-infiltrative subtypes. They found positive im-
munoreactivity of tumor cells for calponin in 18.7% 
of all cases investigated. However, while calponin ex-
pression was found in only one (5.5%) case of nodular 
BCC, in the infiltrative component, it was found in 5 
(35.7%) of 14 infiltrative or mixed nodular-infiltrative 
subtypes. This difference was statistically significant. 
On the basis of these observations it may be hypoth-
esized that aberrant (over) production of calponin in 
BCC cells is responsible for local invasiveness of the 
tumor and more aggressive biological behavior. In a 
later study, Uzquiano et al. (5) analyzed an identical 
number of cases consisting of 10 metastatic BCCs, 
12 nodular BCCs, and 10 infiltrative BCCs.They used 
Table 1. A summary of the immunohistochemical findings in the set of 37 basal cell carcinoma (BCC) we 
investigated 
BCC subtype n Calponin expression in tumor tissue Calponin expression in stroma  
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positive: 0 (0%)




























negative: 3 (42.9%) 
positive: 4 (57.1%)
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the same cut-off level of staining positivity (≥5%) as 
Lee et al. (10). In spite of that, they did not find a sta-
tistically significant difference in the expression of 
calponin among the distinct BCC subtypes. In their 
series, calponin immunoreactivity was found in 50% 
of nodular BCCs, 60% of infiltrative BCCs, and 30% of 
metastatic BCCs. 
In our analysis of 37 primary cutaneous BCCs, we 
found that immunohistochemical expression of cal-
ponin in tumor tissue did not correlate with more 
aggressive tumor phenotypes. These findings are 
similar to the results reported by Uzquiano et al. (5) 
and discrepant to those of Lee et al. (10). On the other 
hand, we observed an association between infiltra-
tive growth features of cancer and strong expression 
of calponin in peritumorous stromal cells. Since nor-
mal fibroblasts do not tend to produce calponin, such 
findings indicate their transformation into myofibro-
blasts, probably induced by molecular interactions 
between neoplastic cells and the surrounding stro-
ma. There is now increasing evidence that biological 
behavior of cutaneous BCC is modulated by specific 
epithelial-mesenchymal interplay (17,18). Bearing 
in mind the stroma-dependency as a characteristic 
feature of this malignancy, it can be hypothesized 
that the growth pattern of BCC may be influenced by 
calponin production in the stromal myofibroblasts 
around the tumor nests, rather than in the neoplastic 
cells alone. Active myofibroblasts may facilitate tu-
mor cells invasion into the connective tissue through 
increased motility, as well as through the release of 
metalloproteinases, which degrade the surround-
ing mesenchymal matrix. Until now, there have been 
no reports about calponin expression in the peritu-
morous stroma in cutaneous BCC, since both papers 
above (5,10) did not mention it. We thus had no op-
portunity to compare our results with other observa-
tions. Therefore, we believe that this area represents a 
promising subject for further studies. 
CONCLUSION
Our study demonstrated that neoplastic cells in 
cutaneous BCC commonly produce calponin regard-
less of histological subtypes. We also found that ex-
pression of calponin in tumor tissue was not associ-
ated with aggressive tumor phenotypes. Therefore, 
immunohistochemical application of anti-calponin 
antibodies alone does not seem to be a useful prog-
nostic marker for this malignancy. However, since 
some BCCs with infiltrative growth patterns strongly 
expressed calponin in peritumorous stroma, this find-
ing may more reliably reflect the biological behav-
ior of cancer and should be better explained in the 
future. Further research is needed to elucidate the 
mechanism and role of calponin in BCC biology. 
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